Ipsen S.A. (IPN.PA)
| Previous close | 123.10 |
| Open | 122.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 119.40 - 123.10 |
| 52-week range | 99.70 - 130.70 |
| Volume | |
| Avg. volume | 69,519 |
| Market cap | 10.002B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | 16.28 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.20 (1.00%) |
| Ex-dividend date | 30 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024
Aggregated presentation by day and by market Statement of transactions in own shares from June 3 to June 7, 2024 Name of issuer Identification code of issuer (Legal Entity Identifier) Day of transaction Identification code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares * Market (MIC Code) IPSEN 549300M6SGDPB4Z94P11 03/06/2024 FR0010259150 3 100 120,9943 XPAR IPSEN 549300M6SGDPB4Z94P11 04/06/2024 FR0010259150 3 100 121,57
- GlobeNewswire
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE trial dataPrimary biliary cholangitis impacts approximately 100,000 people in the US and is growing in global prevalence. If inadequately treated, it can cause liver failureU.S. approval of Iqirvo establishes Ipsen as a leader in the treatment of rare cholestatic liver diseases PARIS,
- GlobeNewswire
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
Using Marengo’s TriSTAR platform, Ipsen and Marengo teams expand their ongoing oncology research to include up to two additional assets in new early development collaborationResearch will focus on using Marengo’s TriSTAR platform to reinvigorate and mobilize selective Vβ T cells to boost anti-tumor activity in patients with traditionally difficult-to-treat ‘cold’ tumors PARIS, FRANCE, and CAMBRIDGE, MA, U.S., 07 June 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Marengo Therapeutics Inc, a clinic
